Chinese PLA General Hospital
Beijing, Beijing Municipality, 100853, China
Location status: Recruiting
Location contact
Ping Liang, Doctor
CONTACT
NCT Number: NCT06559761
Hepatocellular carcinoma (HCC) is a highly heterogeneous malignant tumor with significant differences in invasion, proliferation ability and patient prognosis. Currently, there is a lack of non-invasive and simple indicators to predict the prognosis of HCC patients and assist clinical decision-making. The identification of HCC macroscopic or histopathological classification requires large pathological specimens obtained through surgical resection, but only about 20% of patients are eligible for surgical treatment. Moreover, most liver cancer diagnoses can be confirmed by imaging examinations without relying on pathological results. For patients who have not undergone surgical resection, the lack of histopathological information during treatment means that there is no basis for judging tumor proliferation and obtaining rich prognostic information. Therefore, evaluating the invasion and proliferation ability of HCC based on macroscopic imaging assessment has important implications for guiding individualized diagnosis and treatment throughout the entire process including surgical strategy guidance, local treatment selection, systemic therapy planning as well as patient follow-up and prognosis evaluation.
Ultrasound and MRI are ideal entry points as first-line imaging methods for liver cancer diagnosis. This study aims to evaluate HCC macroscopic or histopathological classification based on multimodal imaging (ultrasound, CT, MRI), thereby assessing its invasion and proliferation ability which has important implications for guiding individualized diagnosis and treatment throughout the entire process including surgical strategy guidance, local treatment selection, systemic therapy planning as well as patient follow-up and prognosis evaluation.
By analyzing macroscopic image features we aim to explore their cross-scale correlations with HCC macroscopic classification,histopathological classification,and gene molecular typing.
Interested in participating?
Request Info18 year–80 year
All sexes
Observational
Beijing, Beijing Municipality, 100853, China
Location status: Recruiting
Ping Liang, Doctor
CONTACT
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
· Not meeting any one of the inclusion criteria or being unwilling/unable to follow-up.
According to guideline recommended procedure of hepatectomy
Time frame: through study completion, an average of 1 year
OS was defined as death related to any cause and was indexed from the date of ablation or surgery until last contact or death
Time frame: through study completion, an average of 1 year
DFS was defined as the time interval between first treatment and recurrence or death, whichever occurred earlier
Time frame: through study completion, an average of 1 year
MRI or ultrasound Imaging features of the four types
Time frame: through study completion, an average of 1 year
Quantification of immune cells of the resected liver tumour using HE staining and immunohistological staining to assess molecular marker and cell infiltration in tumor and liver parenchyma
Time frame: through study completion, an average of 1 year
mRNA sequencing data of the resected liver tumour and peritumor parenchyma specimen to assess the gene enrichment
Contact information is provided by the study sponsor or research team.
Chinese PLA General Hospital
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06230328
Adenocarcinoma, Carcinoma
Barretos, Brazil
View Trial DetailsNCT07419841
Adenocarcinoma, Carcinoma
Omaha, Nebraska, United States
View Trial DetailsNCT04912765
Adenocarcinoma, Carcinoma
Singapore
View Trial DetailsNCT06811116
Adenocarcinoma, Advanced Hepatocellular Carcinoma
Irvine, California, United States
View Trial Details